Therapeutic BCG Vaccines Market Report 2026

Therapeutic BCG Vaccines Market Overview

• Therapeutic BCG Vaccines market size has reached to $59.09 billion in 2025 • Expected to grow to $80.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Fighting Tuberculosis Surging Global Cases Propel Growth In The Therapeutic Bcg Vaccine Market • Market Trend: Innovative Therapeutic Applications Of Bcg Immunotherapy • Asia-Pacific was the largest region in 2025.

What Is Covered Under Therapeutic BCG Vaccines Market?

Therapeutic BCG vaccine refers to a vaccine that offers defense against TB, also referred to as tuberculosis. The therapeutic BCG vaccine, which stands for the Bacillus Calmette-Guérin vaccine, is not a part of the standard NHS vaccination schedule. Only one dose of the BCG vaccine should be administered in a lifetime. The major types of therapeutic BCG vaccines are therapy BCG and immune BCG. Therapy BCG refers to a kind of intravesical immunotherapy that aids the immune system's destruction of cancer cells and is frequently used to treat bladder cancer in its early stages. By demographics, BCG vaccines can be used on pediatrics and adults. These are used by several end-users, such as hospitals, clinics, and other end-users.

What Is The Therapeutic BCG Vaccines Market Growth Forecast?

The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $80.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for personalized vaccines, technological advancements in vaccine delivery, rising focus on immuno-oncology applications, expansion of public health programs, growing investment in biotech innovations. Major trends in the forecast period include personalized bcg therapy development, vaccine delivery innovations, expanded research in tb immunotherapy, combination therapies with bcg, government-funded immunization programs.

Global Therapeutic BCG Vaccines Market Segmentation

1) By Type: Therapy BCG, Other Types 2) By Demographics: Pediatrics, Adults 3) By End Use: Hospitals, Clinics, Other End Users

What Is The Driver Of The Therapeutic BCG Vaccines Market?

The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, such as adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine industry.

Key Players In The Global Therapeutic BCG Vaccines Market

Major companies operating in the therapeutic bcg vaccines market are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, Bharat Biotech International Ltd., Shanghai Institute of Biological Products Co. Ltd., Instituto Butantan, BioCen, Panacea Biotec Ltd., Institute Pasteur de Tunis, Korean BCG Vaccine Institute

Global Therapeutic BCG Vaccines Market Trends and Insights

Major companies operating in the therapeutic BCG vaccine market are focused on innovating vaccines for potential therapeutic applications in various medical conditions, such as BCG immunotherapy, to expand their customer base and meet growing patient needs. BCG (Bacillus Calmette-Guérin) immunotherapy refers to the use of the BCG vaccine as a form of immunotherapy to treat certain types of cancer, particularly bladder cancer. For instance, in July 2023, The Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, received government approval to export its BCG vaccine to Canada for immunotherapeutic use in treating bladder cancer. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin), is intended for intravenous instillation. The vaccine is available in 40 mg and 80 mg presentations. As an integral part of the therapy, the vaccine is administered directly into the bladder through a catheter, where it remains in the bladder lining for a specified duration. This targeted approach aims to impact cancer cells effectively while minimizing impact on other parts of the body.

What Are Latest Mergers And Acquisitions In The Therapeutic BCG Vaccines Market?

In May 2024, ImmunityBio, a US-based biopharmaceutical company focused on cancer immunotherapy, partnered with Serum Institute of India to scale manufacturing and expand global access to its immunotherapy products. With this partnership, ImmunityBio aims to secure reliable global manufacturing of both standard and recombinant BCG (iBCG) for use in its ANKTIVA® therapy, enabling scale-up of therapeutic BCG applications in cancer, while Serum Institute of India expands its presence in the therapeutic BCG market. Serum Institute of India is an India-based vaccine manufacturer producing standard and engineered BCG strains for global distribution.

Regional Insights

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Therapeutic BCG Vaccines Market?

The therapeutic BCG vaccines market consists of sales of vectors, peptides, proteins, DNA, and dendritic cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Therapeutic BCG Vaccines Market Report 2026?

The therapeutic bcg vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic bcg vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.